Gilead has finally got the FDA's nod for its novel HIV therapy, the long-acting capsid inhibitor lenacapavir, after previous issues with the vials in which the drug had been stored. The approval is in patients with multidrug-resistant HIV, who account for around 2% of the total HIV population, the company estimates.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,